Roche’s (RHHBY.OB) supplemental Biologics License Application seeking approval for Tecentriq in combination with Abraxane for the first-line treatment of people with PD-L1-positive, metastatic triple-negative breast cancer awaits the FDA decision on March 12, 2019.Tecentriq in combination with carboplatin and etoposide (chemotherapy), for the first-line treatment of people with extensive-stage small cell lung cancer, is also under FDA review, with a decision expected by March 18, 2019.Tecentriq is currently approved for the treatment of patients with advanced urothelial carcinoma and patients with metastatic non-small cell lung cancer (NSCLC) in the European Union, the United States, and more than 85 countries.The drug generated annual sales of 772 million Swiss francs in 2018, up 59% over the prior year. RHHBY.OB closed Tuesday’s trading at $34.81, up 0.59%.